More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$5.59B
EPS
2.26
P/E ratio
57.3
Price to sales
3.99
Dividend yield
--
Beta
0.626647
Previous close
$120.92
Today's open
$120.78
Day's range
$120.24 - $123.50
52 week range
$51 - $132
show more
CEO
Christopher A. Simon
Employees
3009
Headquarters
Boston, MA
Exchange
New York Stock Exchange
Shares outstanding
45537511
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
Haemonetics Announces CE Mark Certification for the VASCADE MVP® XL Venous Vascular Closure System
First Commercial European Procedures Completed in Germany, Italy and the UK BOSTON, Nov. 18, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced CE Mark certification for the VASCADE MVP® XL venous vascular closure system, enabling Haemonetics to broaden its global presence and bring new vascular closure benefits to physicians in the European Union (EU) and other geographies that recognize CE marking. The first European procedures with the VASCADE MVP XL system were performed in October by Prof.
PRNewsWire • Nov 18, 2026

Ariel Small Cap Value Q3 2026 Portfolio Activity
Bar-code manufacturer Zebra Technologies was the top contributor during the quarter following a strong earnings report and raise to full-year guidance. Norwegian Cruise Line Holdings declined during the quarter as investors focused on weaker yield expectations, uneven booking trends and ongoing execution challenges. During the quarter, we acquired ADI Global Distribution following its spin-off from our existing holding, Resideo Technologies.
Seeking Alpha • Nov 13, 2026

International Markets and Haemonetics (HAE): A Deep Dive for Investors
Review Haemonetics' (HAE) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Zacks Investment Research • Nov 9, 2026

Haemonetics Q2 Earnings Call Highlights
Haemonetics NYSE: HAE raised its fiscal 2027 revenue growth outlook after reporting double-digit organic growth in its second quarter, but lowered its operating margin expansion forecast as it invests to support an expanded relationship with plasma collector CSL.
MarketBeat • Nov 7, 2026

Haemonetics Corporation (HAE) Q2 2027 Earnings Call Transcript
Haemonetics Corporation (HAE) Q2 2027 Earnings Call Transcript
Seeking Alpha • Nov 5, 2026

Haemonetics Corporation Announces Second Quarter Fiscal 2027 Financial Results Available on Investor Relations Website
Financial release and supplemental presentation accessible online BOSTON, Nov. 5, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2027, which ended September 26, 2026, are available on the Company's Investor Relations website at www.haemonetics.com. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.
PRNewsWire • Nov 5, 2026

Haemonetics (HAE) Q2 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.35 per share, beating the Zacks Consensus Estimate of $1.3 per share. This compares to earnings of $1.27 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Haemonetics Corporation (HAE) Hits Fresh High: Is There Still Room to Run?
Haemonetics (HAE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Investment Research • Nov 5, 2026

GEHC vs. HAE: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Products stocks have likely encountered both GE HealthCare Technologies (GEHC) and Haemonetics (HAE). But which of these two stocks is more attractive to value investors?
Zacks Investment Research • Oct 29, 2026

Blood Plasma Name Hits Highs On FDA Approval As Earnings Loom
Haemonetics provides tools for blood products management such as plasma collection and providing systems, training and services for blood collection.
Investors Business Daily • Oct 28, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Haemonetics Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.